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A B S T R A C T
To determine the newborn infection rate with group B streptococcus infection (GBS) before and after American Acad-
emy of Pediatrics Protocol (AAP) implementation in Croatia, antenatal risk factors, neonatal outcome and necessity for
introducing national policy for intrapartum chemoprophylaxis. To evaluate the role of intrapartum chemoprophylaxis in
preterm labor at <37 weeks of gestation, premature rupture of membranes at <37 weeks of gestation, fever during labor,
ruptures of membranes >18 hours before delivery and previous delivery of a sibling with GBS disease. A total of 784 neo-
nates admitted to the Neonatal Intensive Care Unit, from 1 January 2005 to 31 December 2005. 60 (10/1000 live born) de-
veloped early-onset infection (EOGBS). The dominant presentation for EOGBS was sepsis (65%), pneumonia (32.2%)
and meningitis (3%). Mean gestational age was 34.5 (±5.3) weeks. There were 2 neonatal deaths (3%) in EOGBS, both
preterm. EOGBS disease was associated with following risk factors: rupture of the membranes >12 hours (49.3%),
chorioamnionitis (11.9%), status post cerclage (10.4%), diabetes mellitus (4.5%), delivery out of hospital (3%), uroin-
fection (1.5%). After AAP implementation the incidence of GBS infection decreased from 15/1000 to 10/1000 of live born
infants. The mortality from EOGBS dropped from 5% to 3 %. The incidence of GBS infection in our study was consider-
ably higher than in all current reports. Reasons for that can be inadequate perinatal screen in some parts of the country
and no established policy for intrapartum antibiotic treatment of women with risk factors. Our results documented that
intrapartum chemo-prophylaxis for GBS infection significantly reduces perinatal mortality due to neonatal infection
and sepsis.
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Introduction
Colonization with group B beta-hemolytic strepto-
cocci (GBS) at any time during pregnancy is an impor-
tant risk factor for neonatal sepsis and it has long been
recognized as a frequent cause of morbidity in parturient
women, and of mortality and morbidity in the newborn
infants1. Early onset group B streptococcal infection
(EOGBS) is one of the major neonatal infections in devel-
oping countries but also in industrialized ones2. The clin-
ical features for EOGBS and LOGBS (Late onset of
group B neonatal infection) disease are summarized in
Table 1.
In many countries, in particular in US, several recom-
mendations have been proposed to prevent the perinatal
GBS infection4. The most important problem in the pre-
vention programme is the identification of the cases to
treat, since it is not possible to give antibiotics to all the
women. In 1996, the federal Centers for Disease Control
and Prevention (CDC), the American College of Obstetri-
cians and Gynecologists (ACOG) and the American Acad-
emy of Pediatrics (AAP) recommended an approach for
prevention of early onset GBS infection in neonates
based on risk factors. These strategies, either a risk-
based or a culture-based program, have been responsible
for reduced incidence of GBS newborn disease from 1.7
to 0.4/1000 live births in the years 1993 to 1999 in the
United States5. In Croatia we combine two strategies for
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the identification of the women to be treated, one risk
based and the other screening based6. The incidence of
EOGBS infection in Croatia before the implementation
of the Protocol was much higher than in most of the
studies (15/1000 live births; mortality rate 5%), so we be-
lieved that intrapartum chemoprophylaxis in risk pa-
tients can reduce the mortality and consequences of GBS
infection in newborns2,6.
The aim of our study was to compare the newborn in-
fection rate with GBS before and after the introduction
of AAP protocol. Other objective was to evaluate the
prevalence of antenatal risk factors and mortality rates
in high risk obstetrical patients, and to propose the intro-
duction of intrapartum chemo-prophylaxis as a part of
our national policy.
Patients and Methods
A prospective study of all newborn babies admitted to
the Neonatal Intensive Care Unit (NICU) at Department
of Obstetrics and Gynecology, School of Medicine, Uni-
versity of Zagreb, for the year 2005 was analyzed to de-
termine the incidence of GBS infection before and after
AAP implementation in Croatia, antenatal risk factors
and neonatal outcome.
Maternal screening for vaginal group B streptococci is
not a routine and there is no written policy for intrapar-
tum antibiotic treatment of high risk patients. Women
who develop fever or who have prolonged rupture of
membranes with chorioamnionitis often receive intra-
partum antibiotics. There were 48 women in our study
who received prophylaxis (2 g i.v. of Ampicillin initial
dose and 1 g every four hours during the labour).
Surface swabs (skin) and gastric aspirat are taken
from every newborn admitted to the NICU. Blood culture
from the umbilical cord also collected at the time of deliv-
ery in a delivery room from any baby born to a mother
with a fever or if the membranes have been ruptured for
over 16 hours. Swabs and blood culture are plated on to
blood agar and incubated in 5 % CO2. If beta haemolytic
colonies are penicilin sensitive they are serotyped to con-
firm group B streptococci.
Definite early onset group B streptococcal infection
was defined as a positive blood and/or cerebrospinal fluid
culture in the context of clinical sepsis in a baby aged less
than 48 hours. Probable EOGBS infection was defined as
clinical signs consistent with EOGBS infection in a baby
under 48 hours old, colonized with group B streptococci7.
Definition of definite Early Onset Group B
Streptococcal disease
Sepsis: a pure growth of group streptococci from one
or more blood culture bottles associated with clinical sep-
sis. Meningitis: a pre growth of group B streptococci from
cerebrospinal fluid or pleocystosis and positive blood cul-
tures. Pneumonia: respiratory distress cosistent with
pneumonia and the radiographic appearance of streaky
opacities or confluent lobar opacification persisting for
more than 24 hours, in addition to a positive blood cul-
ture for group B streptococci.
Definition of probable Early Onset Group B
Streptococcal disease
All infants had significant laboratory findings for in-
fection (high CRP, more than 10% bands in peripheral
blood picture/left shift or thrombocytopenia) and one of
the following: Probable group B streptococcal pneumo-
nia: respiratory distress consistent with pneumonia and
the radiographic appearance of streaky densities or con-
fluent lobar opacification persisting for more than 24
hours, in an infant colonized with group B streptococci.
Probable group B streptococcal sepsis: an infant colo-
nized with group B streptococci in the presence of two of
the following clinical sings: respiratory deteration, throm-
bocytopenia, bowel stasis or poor perfusion/ hypotension.
For statistical analyses, we used chi-square test, Stu-
dent’s t-test and Mann Whitney test. We considered
P<0.05 to be statistically significant.
Results
During the period between 1 January 2005 and 31 De-
cember 2005 there were 784 infants admitted at the
NICU. All results are shown in the tables.
From that number 152 (19.4%) infants had clear clini-
cal signs of early onset infection in first 24 hours of life.
The newborn infection rate with EOGBS infection was
significantly lower after the introduction of AAP protocol
(p=0.0013).
Sixty seven neonates had EOGBS disease, 60 (90%)
positive cultures (definitive infection), and 7 (10%) prob-
able infection. The incidence of definite EOGBS infection
was 10 per 1000 live births and the incidence of probable
infection was 2 per 1000 live births.
After year 2000 and intrapartum chemoprophylaxis
the incidence of GBS decreased to 10/1000 live born in-
fants and the mortality dropped to 3% with increased in-
cidence of Gram negative microorganisms and decreased
incidence of Gram positive.
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TABLE 1
COMPARISON OF EARLY ONSET GROUP B STREPTOCOCCAL
INFECTION AND LATE ONSET GROUP B STREPTOCOCCAL
INFECTION
Feature EOGBS LOGBS
Age range <7 days 7 days–3 months
Median age at onset 1 hour 27 days
Maternal complication Common Uncommon
Incidence of prematurity Frequent (30%) Uncommon
Mortality rate 5–20%* 2–6%
*<10% in term infants (modified with permission from Baker,
C. J., N. A. Halsey, A. Schuchat, AAP Modified guidelines for pre-
vention of early-onset group B streptococcal disease. Pediatrics.,
103 (1999) 71)3
The dominant presentation for definite EOGBS dis-
ease was sepsis with an increased incidence of meningi-
tis. Of 7 neonates with probable infection, 4 (57.2%) had
sepsis, and 3 (42.9%) had pneumonia.
Table 5 shows the most common risk factors for
EOGBS. We found decreased incidence in status post
cerclage (p<0.05) and delivery out of the hospital (p<
0.05) in compared years.Twelve neonates were not con-
sidered at high risk for EOGBS infection.
Ten neonates with EOGBS disease were on the artifi-
cial ventilation, the average duration of ventilation was
12 days. The gestational age of definite cases varied from
28 to 42 weeks, with a mean (SD) of 34.5 (±5.3) weeks. 28
(46.7%) of 60 neonates with definite EOGBS infection
were preterm (<37 weeks gestation). The mean gesta-
tional age of babies with probable EOGBS infection was
36.5 (±5.2) weeks. The rate of neonates small for ages in
group with EOGBS infection was 83.5 %. Two (3%) neo-
natal deaths were attributed to EOGBS infection, and all
of them were neonates with definite infection. Two neo-
nates who died were both preterm and their gestational
ages were 28 and 33 weeks. GBS was found in cervical
smears in 7 of 67 mothers (10%) of neonates with EOGBS
disease.
Discussion
In Croatia, before year 2000, when we started with
AAP guidelines, the incidence of GBS was 15/1000 live
born infants, and mortality from EOGBS was 5%2. After
year 2000 and intrapartum chemoprophylaxis the inci-
dence of GBS decreased to 10/1000 live born infants, and
the mortality rate dropped to 3% with increase incidence
of Gram negative microorganisms and decrease inci-
dence of Gram positive (Table 3). Our data suggest that
the incidence of EOGBS infection in our institution
(10/1000 live births) is still higher than in most other re-
ports (0.4–5/1000 live births)8. In the field of perinatal
medicine there was an evident increase of GBS infe-
ction9. The first cases of human infection with GBS were
reported in the 1930s. This organism was virtually un-
known to the clinicians until 1964, when the first study
of perinatal GBS infections was published10. By the 1970’s,
GBS emerged dramatically as the leading cause of mater-
nal and neonatal infection with fatality rates of 20–
50%11. In the pre-prevention era active surveillance for
invasive neonatal GBS disease estimated that approxi-
mately 6,100 early-onset cases and 1,400 late-onset cases
occur annually in the United States12. In 1996, the first
national consensus guidelines were released. Since then,
there has been a 70% reduction in early-onset neonatal
GBS infection, but no decrease in late-onset neonatal
GBS disease13. In 2002, new AAP guidelines were intro-
duced recommending: 1) solely screen based prevention
strategy, 2) new algorithm for patients with penicillin al-
lergy and 3) more specific practices in certain clinical
scenarios14. After prevention implementation incidence
of GBS infection declined by 70% to a rate of 0.5/1000
live births in the United States15.Regarding the litera-
ture, pregnancy itself does not influence colonization
rates16. Maternal colonization rates in the United States
are 26%17. Regarding our data GBS was found in cervical
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TABLE 2
ADMISSION RATE IN NEONATAL INTENSIVE CARE UNIT AND












1999 4817 761 15.8 201 26.4
2005 4130 784 18.9 152 19.4
p NS 0.0013
NICU – Neonatal Intensive Care Unit; EOGBS – Early Onset
Group B Streptococcal Infection
TABLE 3
COMPARISON OF THE MOST COMMON ISOLATES IN EARLY
ONSET GROUP B STREPTOCOCCAL INFECTION IN COMPARED
PERIOD
Isolates (%) Year 1999 Year 2005 p
GBS 59.8 44.1 P=0.0000
E. coli 29.8 40.1 P=0.0000
Enterococcus 7.6 11.2 P=0.156
Candida 1.3 2.6 P=0.065
Pseudomonas 1.5 0.7 P=0.1309
GBS – Group B Streptococcus
TABLE 4
DOMINANT PRESENTATION OF EARLY ONSET GROUP B







Sepsis 63 65 NS
Pneumonia 36 32.2 NS
Meningitis 1 3 NS
TABLE 5
THE INCIDENCE OF DOMINANT RISK FACTORS FOR EARLY








RVP  12 hours 46.6 49.3 NS
Chorioamnionitis 10.7 11.9 NS
Status post cerclage 15.2 10.4 NS
Diabetes mellitus 4.1 4.5 NS
Delivery out of hospital 5.3 3.0 NS
Uroinfectio in pregnancy 1.3 1.5 NS
RVP – Premature rupture of membranes
smears in 7 of 67 mothers (10%) of neonates with EOGBS
disease. Neonatal GBS incidence date for Europe have
been reported only from the Netherlands (1.9/1000 live
births), England (0.72/1000 live births) and Germany
(0.47/1000 live births)18.
In our research we confirmed our hypothesis in de-
creasing the incidence and the mortality rate of EOGBS
in newborns after introducing intrapartum chemo-pro-
phylaxis in risk pregnancies (Table 2), but we are still not
satisfied. Reasons for that can be in our definition of
EOGBS infection3, higher rate of rectovaginal GBS car-
riage of pregnant women in Croatia, no consistent policy
for intrapartum antibiotic treatment of women with risk
factors, poor perinatal screening in some parts of the
country and differences in ethnic or specifically genetic
factors between the population in Croatia and in the
United States and western European countries.
The prevalence of risk based strategy of identifying
candidates for treatment may be more effective. Our re-
sults shows that more than 80% of women who delivered
neonates with EOGBS disease had one of the risk factors
from AAP guidelines, but we noticed two more which we
did not find in other studies (status post cerclage 10.4%
and delivery out of the hospital 3%). We also found their
decreasing incidence after introducing the Protocole (Ta-
ble 5), but without statistically importance.
More then 90% of EOGBS disease and almost all fatal
infections occur within the first day of life, with a median
age at onset of 1 hour8. The dominant presentation for
EOGBS disease in our study before and after chemo-
prophylaxis is sepsis (63% vs. 65%) with or without of re-
spiratory distress (RDS) and pneumonia (36% vs. 32.2%).
Meningitis occurs in an estimated 5% to 10% of EOGBS
cases in the literature and 1% and 3% in our study19 (Ta-
ble 4). Antibiotic therapy (Penicillin and Garamycin) was
immediately introduced to all our infants with clear clini-
cal signs of early onset infection. After 48 hours, antibi-
otic therapy was modified according to the result of an
antibiogram. Infection caused by GBS was treated with
penicillin, caused by E. coli was treated with Garamycin,
caused by Enterococcus was treated by Ampicillin, cau-
sed by Candida was treated by Diflucan, and caused by
Pseudomonas was treated by Cefepim. Fatal infection is
associated commonly with fulminant and overwhelming
EOGBS disease and with the irreversible consequences
of LOGBS infection. From the data in the literature, the
birth weight-specific mortality for infants with bacte-
riemia remains increased 25–30% for neonates weighing
less than 2.5 kg and 2–4% for neonates more than 2.5 kg20.
The mortality rate according our results decreased from
5% in 1999 to 3% in 2005 all due to prematurity.
Despite identification of intrapartum chemoprophy-
laxis as an effective intervention, controversy continued
to surround prevention methods of identifying candi-
dates for chemoprophylaxis21. Competing strategies in-
cluded: 1) monitoring women for known obstetric risk
factors (fever, preterm labor, prolonged membrane rup-
ture) during labor and 2) performing culture-based
screening of women before labor and to identify women
colonized with GBS. Screening proponents also disagre-
ed about the best time to perform screening22.
Either prenatal GBS screening or a risk-based strat-
egy could potentially prevent a substantial portion of
GBS cases22. In selecting the patients who should receive
intrapartum prophylaxis, recent data suggested that
screening programs for the detection of GBS prevalence
may be more effective than risk- based strategies for pre-
vention of EOGBS. Combined vaginal and rectal swabs,
collected between 35 and 37 weeks gestation provide op-
timum conditions to detect presence of the infection18.
Sepsis caused by other organisms is more often a disease
of prematurity19. Intrapartum antibiotic prophylaxis
seemes to be efficient against the EOGBS sepsis by inter-
rupting vertical GBS transmission and it is now a largely
preventable public health problem20.
It seems important to develop and implement Cro-
atian national prevention policy for prevention and
treatment of peripartal GBS infection. Studies indicate
that intrapartal prophylaxis of GBS carriers and selec-
tive administration of antibiotics to the newborns may
reduce neonatal GBS sepsis to a level of 80–95%11. Inter-
ruption of GBS vertical transmission is dependent upon
maternal treatment before fetal colonization. Intrapar-
tum chemoprophylaxis must be selected based on mater-
nal allergy history and susceptibility of GBS isolates23.
Intravenous penicillin G is the preferred antibiotic, with
ampicillin as an alternative. Penicillin G should be ad-
ministered at least four hours before delivery for maxi-
mum effectiveness. Cefazolin is recommended in women
allergic to penicillin who are at low risk of anaphylaxis.
Clindamycin and erythromycin are options for women at
high risk for anaphylaxis, and vancomycin should be
used in women allergic to penicillin and whose cultures
indicate resistance to clindamycin and erithromycin or
when suspectibility is unknown. However, the severity of
ampicillin-resistant E. coli sepsis and its occurrence after
maternal antibiotics suggest caution regarding the use of
ampicillin instead of penicillin for GBS prophylaxis21. A
written protocol for prevention of GBS infection in new-
born must be adopted in every delivery centre.
The population reported in our study may not be typi-
cal of the entire Croatian population, and it is likely that
the incidence of GBS infection is different in other parts
of Croatia. Studies on the incidence in different regions
are needed to establish a basis for trials on different
strategies to reduce EOGBS infection.
Continued efforts to eradicate GBS newborn disease
require an early detection of the pathogen, better under-
standing of the colonization and transmission, imple-
mentation of effective sampling techniques and therapy.
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MATERNALNA INFEKCIJA HEMOLITI^KIM STREPTOKOKOM GRUPE B,
NEONATALNI ISHOD I ULOGA POSTUPAKA PREVENCIJE
S A @ E T A K
Kolonizacija beta hemoliti~kim streptokokom iz grupe B tijekom trudno}e ubraja se u visoko rizi~ni ~imbenik za
neonatalni morbiditet i mortalitet, a u zemljama u razvoju vode}i je uzrok neonatalne infekcije i te{ke neonatalne
sepse. Posljedi~no tome, 2000. godine uveli smo Protokol za prevenciju perinatalne infekcije beta hemoliti~kim strepto-
kokom i u ovom istra`ivanju analizirali rizi~ne ~imbenike za nastanak infekcije, u~estalost novoro|ena~ke infekcije
beta hemoliti~kim streptokokom grupe B prije i nakon uvo|enja Protokola te neonatalni ishod u uspore|ivanim raz-
dobljima. Utvrdili smo da je uvo|enjem Protokola u~estalost novoro|ena~ke infekcije pala s 15/1000 `ivoro|ene djece
na 10/1000 `ivoro|ene djece, a mortalitet s 5 na 3%. Dominantna klini~ka slika u infekciji novoro|en~adi beta hemoli-
ti~kim streptokokom u promatranim razdobljima je sepsa.Naj~e{}i rizi~ni ~imbenici za nastanak novoro|ena~ke infek-
cije bili su prijevremeno prsnu}e membrana (49,3%) te korioamnionitis (11,9%). U~estalost neonatalne infekcije beta
hemoliti~kim streptokokom nakon uvo|enja Protokola u na{em se istra`ivanju pokazala i dalje visokom u usporedbi s
podacima iz literature. Uzroci mogu biti u neadekvatnom probiru pacijentica te nedostatku odredbe za obaveznu intra-
partalnu kemoprofilaksu rodilja s rizi~nim ~imbenicima.
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